These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24892810)

  • 61. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
    Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
    J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.
    Dupuy FP; Kant S; Barbé A; Routy JP; Bruneau J; Lebouché B; Tremblay C; Pazgier M; Finzi A; Bernard NF
    mBio; 2019 Dec; 10(6):. PubMed ID: 31848282
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
    Khattar SK; Samal S; LaBranche CC; Montefiori DC; Collins PL; Samal SK
    PLoS One; 2013; 8(10):e78521. PubMed ID: 24098600
    [TBL] [Abstract][Full Text] [Related]  

  • 65. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cross-neutralizing antibody profile of Chinese HIV-1-infected individuals and the viral envelope features from elite neutralizers.
    Ren C; Liu S; Li Y; Zhuang M; Yu H; Wang J; Sun F; Li D; Zhang H; Liu W; Liang S; Zhong P; Ling H
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):472-80. PubMed ID: 25202919
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".
    Sun Z; Li J; Hu X; Shao Y; Zhang MY
    Antiviral Res; 2015 Jun; 118():1-9. PubMed ID: 25770672
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
    J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
    J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.
    Li Y; Svehla K; Louder MK; Wycuff D; Phogat S; Tang M; Migueles SA; Wu X; Phogat A; Shaw GM; Connors M; Hoxie J; Mascola JR; Wyatt R
    J Virol; 2009 Jan; 83(2):1045-59. PubMed ID: 19004942
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Common antibody dependent cell mediated cytotoxicity (ADCC) antibody epitopes of HIV-1 CRF01_AE Env and Gag in early HIV-1 infected individuals.
    Sangjan S; Ampol S; Tabprasit S; Horthongkham N; Chuenchitra T; Ekpo P; Kantakamalakul W
    Asian Pac J Allergy Immunol; 2019 Mar; 37(1):43-50. PubMed ID: 29602284
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Longitudinal analysis of subtype C envelope tropism for memory CD4
    Gartner MJ; Gorry PR; Tumpach C; Zhou J; Dantanarayana A; Chang JJ; Angelovich TA; Ellenberg P; Laumaea AE; Nonyane M; Moore PL; Lewin SR; Churchill MJ; Flynn JK; Roche M
    Retrovirology; 2020 Aug; 17(1):24. PubMed ID: 32762760
    [TBL] [Abstract][Full Text] [Related]  

  • 75. HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.
    Rouers A; Klingler J; Su B; Samri A; Laumond G; Even S; Avettand-Fenoel V; Richetta C; Paul N; Boufassa F; Hocqueloux L; Mouquet H; Rouzioux C; Lambotte O; Autran B; Graff-Dubois S; Moog C; Moris A;
    EBioMedicine; 2017 Jul; 21():158-169. PubMed ID: 28615147
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response.
    Wagner GA; Landais E; Caballero G; Phung P; Kosakovsky Pond SL; Poignard P; Richman DD; Little SJ; Smith DM
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28615205
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.
    Chakrabarti BK; Feng Y; Sharma SK; McKee K; Karlsson Hedestam GB; Labranche CC; Montefiori DC; Mascola JR; Wyatt RT
    J Virol; 2013 Dec; 87(24):13239-51. PubMed ID: 24067980
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene.
    de Almeida DV; Macieira KV; Grinsztejn BG; Veloso Dos Santos VG; Guimarães ML
    PLoS One; 2016; 11(12):e0167690. PubMed ID: 27936047
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Polyfunctional Fc Dependent Activity of Antibodies to Native Trimeric Envelope in HIV Elite Controllers.
    Kant S; Zhang N; Barbé A; Routy JP; Tremblay C; Thomas R; Szabo J; Côté P; Trottier B; LeBlanc R; Rouleau D; Harris M; Dupuy FP; Bernard NF
    Front Immunol; 2020; 11():583820. PubMed ID: 33101312
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.